Stock A AGILENT TECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Agilent Technologies, Inc.

Equities

A

US00846U1016

Advanced Medical Equipment & Technology

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
137.7 USD +1.00% Intraday chart for Agilent Technologies, Inc. +3.77% -0.93%
Apr. 22 Bernstein Adjusts Agilent Technologies' Price Target to $130 From $127 MT
Apr. 22 Bernstein Adjusts Price Target on Agilent Technologies to $130 From $127 MT

Valuation

Fiscal Period: Octubre 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 23,442 31,475 47,676 40,957 30,245 40,365 - -
Enterprise Value (EV) 1 24,467 32,393 48,830 42,673 31,390 41,044 41,980 42,936
P/E ratio 22.5 x 44.4 x 40 x 33.1 x 24.7 x 30 x 26.5 x 23.9 x
Yield 0.87% 0.71% 0.49% 0.61% - 0.69% 0.74% 0.81%
Capitalization / Revenue 4.54 x 5.9 x 7.54 x 5.98 x 4.43 x 5.95 x 5.59 x 5.28 x
EV / Revenue 4.74 x 6.07 x 7.73 x 6.23 x 4.59 x 6.05 x 5.81 x 5.61 x
EV / EBITDA 18.6 x 24.3 x 29.6 x 20.8 x 16.1 x 20.8 x 19.2 x 18.2 x
EV / FCF 28.3 x 40.4 x 37.6 x 41.8 x 21.3 x 30.4 x 26.7 x 24.4 x
FCF Yield 3.54% 2.48% 2.66% 2.39% 4.7% 3.29% 3.75% 4.09%
Price to Book 5.07 x 6.54 x 8.83 x 7.8 x 5.23 x 5.93 x 5.41 x 5.07 x
Nbr of stocks (in thousands) 309,468 308,310 302,723 296,041 292,587 293,055 - -
Reference price 2 75.75 102.1 157.5 138.4 103.4 137.7 137.7 137.7
Announcement Date 11/25/19 11/23/20 11/22/21 11/21/22 11/20/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: October 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 5,163 5,339 6,319 6,848 6,833 6,779 7,223 7,647
EBITDA 1 1,315 1,335 1,650 2,051 1,955 1,976 2,186 2,365
EBIT 1 1,202 1,211 1,523 1,857 1,875 1,843 2,036 2,213
Operating Margin 23.28% 22.68% 24.1% 27.12% 27.44% 27.19% 28.19% 28.94%
Earnings before Tax (EBT) 1 919 842 1,360 1,504 1,339 1,444 1,530 1,644
Net income 1 1,071 719 1,210 1,254 1,240 1,347 1,514 1,657
Net margin 20.74% 13.47% 19.15% 18.31% 18.15% 19.87% 20.96% 21.66%
EPS 2 3.370 2.300 3.940 4.180 4.190 4.590 5.202 5.758
Free Cash Flow 1 866 802 1,297 1,021 1,474 1,351 1,574 1,756
FCF margin 16.77% 15.02% 20.53% 14.91% 21.57% 19.93% 21.8% 22.97%
FCF Conversion (EBITDA) 65.86% 60.07% 78.61% 49.78% 75.4% 68.37% 72.02% 74.26%
FCF Conversion (Net income) 80.86% 111.54% 107.19% 81.42% 118.87% 100.33% 104% 106.03%
Dividend per Share 2 0.6560 0.7200 0.7760 0.8400 - 0.9465 1.024 1.112
Announcement Date 11/25/19 11/23/20 11/22/21 11/21/22 11/20/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: Octubre 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 1,660 1,674 1,607 1,718 1,849 1,756 1,717 1,672 1,688 1,658 1,585 1,717 1,803 1,775 1,705
EBITDA 1 403 517 454 503 578 507 473 523 504 464 439.8 519.4 568 500.5 -
EBIT 1 370 486 422 471 538 476 440 490 469 428 400.4 488.2 527.8 480.1 452.7
Operating Margin 22.29% 29.03% 26.26% 27.42% 29.1% 27.11% 25.63% 29.31% 27.78% 25.81% 25.26% 28.43% 29.27% 27.05% 26.56%
Earnings before Tax (EBT) - - - - 455 410 - - - - - - - - -
Net income 1 442 283 274 329 368 352 302 111 475 348 320.6 388.5 427 393.6 375.3
Net margin 26.63% 16.91% 17.05% 19.15% 19.9% 20.05% 17.59% 6.64% 28.14% 20.99% 20.23% 22.62% 23.68% 22.18% 22.02%
EPS 2 1.450 0.9300 0.9100 1.100 1.230 1.190 1.020 0.3800 1.620 1.180 1.085 1.191 1.442 1.359 1.309
Dividend per Share 2 0.1940 0.2100 0.2100 0.2100 0.2100 0.2250 0.2250 - - 0.2360 0.2362 0.2363 0.2363 0.2429 0.2390
Announcement Date 11/22/21 2/22/22 5/24/22 8/16/22 11/21/22 2/28/23 5/23/23 8/15/23 11/20/23 2/27/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: Octubre 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 1,025 918 1,154 1,716 1,145 678 1,615 2,571
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.7795 x 0.6876 x 0.6994 x 0.8367 x 0.5857 x 0.3432 x 0.7385 x 1.087 x
Free Cash Flow 1 866 802 1,297 1,021 1,474 1,351 1,574 1,756
ROE (net income / shareholders' equity) 21.2% 21.3% 26% 29.3% 28.3% 24.4% 23.8% 25.9%
ROA (Net income/ Total Assets) 11% 10.7% 13.1% 14.7% 15.1% 13.8% 14.3% 15.1%
Assets 1 9,742 6,705 9,235 8,502 8,225 9,744 10,563 10,946
Book Value Per Share 2 14.90 15.60 17.80 17.70 19.70 23.20 25.50 27.20
Cash Flow per Share 2 3.210 2.950 4.870 4.370 5.990 5.740 6.840 7.470
Capex 1 155 119 188 291 298 387 357 337
Capex / Sales 3% 2.23% 2.98% 4.25% 4.36% 5.71% 4.94% 4.41%
Announcement Date 11/25/19 11/23/20 11/22/21 11/21/22 11/20/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Agilent Technologies, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
137.7 USD
Average target price
150.5 USD
Spread / Average Target
+9.27%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.93% 40.37B
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.07% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.59% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.26% 133B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.57% 108B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.35% 52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 48.2B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.54% 39.35B
RESMED, INC. Stock ResMed, Inc.
+26.76% 32.03B
ILLUMINA, INC. Stock Illumina, Inc.
-12.18% 19.47B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. A Stock
  4. Financials Agilent Technologies, Inc.